id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321867-7n88rl6p	Jee, J.	Oncologic Immunomodulatory Agents in Patients with Cancer and COVID-19	2020-08-12		.txt	text/plain	3944	259	49	A recent retrospective study found a possible trend toward worse outcomes associated with corticosteroid use in cancer patients, although no analysis was performed to correct for possible selection bias in which sicker patients received those medications [11] . For all analyses we considered the number of patients who developed a primary composite endpoint of respiratory failure (use of nonrebreather, high-flow nasal oxygen, or mechanical ventilation) or death within 28 days of SARS-CoV-2 diagnosis. When patients were stratified by level of respiratory support, corticosteroid use was associated with worse outcomes in the pre-2L oxygen cohort (HR 2.3, 95% CI 1.1-4.9), a trend not observed in the post-2L oxygen (HR 0.9, 95% CI 0.4-1.9) and post-critical cohorts (HR 0.8, 95% CI 0.5-1.4), though these additional analyses were limited by All rights reserved. . https://doi.org/10.1101/2020.08.11.20145458 doi: medRxiv preprint from neutropenia 60 to 180 days prior to SARS-CoV-2 diagnosis did not have worse outcomes.	./cache/cord-321867-7n88rl6p.txt	./txt/cord-321867-7n88rl6p.txt